Heparin Market Analysis

  • Report ID: 3402
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Heparin Market Analysis

Application (Deep Vein Thrombosis, Heart Attacks, Stroke, Atrial Fibrillation)

The heparin market is segmented and analyzed for demand and supply by application into deep vein thrombosis, heart attacks stroke, atrial fibrillation, and others. Out of all, the heart attacks segment is to garner the highest revenue by the end of 2037. This can be attributed to the rising prevalence of heart-related disorders across the globe. According to the World Health Organization, in 2019, around 18 million people die due to cardiovascular diseases and the global share of the CVD death is nearly 32%. Out of these deaths, about 85% were attributed to heart strokes and attacks. Therefore, the rise in cardiovascular problems is driving the growth of the segment. After heart strokes, the atrial fibrillation segment is anticipated to hold the position of second largest segment in the forecast period. This can be attributed to seeing a sizable amount of the global population suffering from this disease.

Route of Administration (Intravenous Infusion, Subcutaneous Injection)

The heparin market is segmented and analyzed for demand and supply by route of administration into subcutaneous injection and intravenous injection. The subcutaneous injection segment had the largest market share owing to the growing demand for home healthcare services, low hospitalized associated costs, and a few more properties like convenience in administration are factors driving the growth of this segment. The higher tolerance rate of patients for subcutaneous heparin performs as a benefit for the segment. The intravenous segment is anticipated to grow at a lucrative rate in the forecast year. The heparin especially unfractionated heparin is conducted through the intravenous route. It acts softly to prevent blood clots and also offers rapid entry into the bloodstream.

Our in-depth analysis of the global market includes the following segments:

         By Product Type

  • Low Molecular Weight Heparin
  • Unfractionated Heparin

         By Route of Administration

  • Intravenous Infusion
  • Subcutaneous Injection

        By Application

  • Deep Vein thrombosis
  • Heart Attack
  • Stroke
  • Atrial Fibrillation
  • Others

          By End-User

  • Hospitals
  • Clinics
  • Others
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3402
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of heparin is evaluated at USD 11.32 billion.

The heparin market size was over USD 10.94 billion in 2024 and is projected to exceed USD 18.82 billion by the end of 2037, witnessing over 4.4% CAGR during the forecast period i.e., between 2025-2037. The higher number of patients with cancer, increased prevalence of chronic disease, rising cases of thromboembolism, and road accidents will boost the market growth.

North America is likely to dominate majority industry share by 2037, propelled by higher number of people developing chronic kidney diseases, followed by surging healthcare expenditure.

The major players in the market include Aspen Holdings, Opocrin S.p.A., LEO Pharma Inc., Baxter, Dr. Reddy’s Laboratories Ltd., Pfizer Inc., B. Braun Medical Inc., Bioiberica S.A.U., Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Fresenius Kabi Canada.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample